MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome
The FDA has cleared MavriX Bio’s IND application for MVX-220, an investigational AAV gene therapy for Angelman syndrome.
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome
FAST launches MavriX Bio and CourageAS Bio, two new biotech companies advancing gene replacement and gene-editing therapies for Angelman syndrome under its AS²Bio accelerator.